PHGE Company Profile and Key Details

BiomX Inc. has 26.55 million shares outstanding. The public float is 18.01 million shares, elevated short interest at 1.91% of float. This equals 501.42 thousand shares. The short ratio is 0.05 days. Institutional investors hold 54.79% of the float. Insiders own 18.81%. OrbiMed Israel BioFund GP Limited Partnership holds 13.77 million shares, Ugwumba Chidozie has 3.00 million shares and Chimovits Erez has 2.31 million shares.

BiomX Inc. generated EPS of -$30.68 over the past year. Five-year average earnings growth is 47.4%. Wall Street analysts project EPS growth of 41.2% annually over the next five years. The latest quarter delivered EPS of $0.00. The next quarter is forecast at -$5.06. Next year's EPS is expected at $17.71. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $26.00 to $2.00. The high target offers 1120.66% upside. The low target suggests -6.1% downside. The mean target is $16.14. This offers 657.75% upside. BiomX Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 12, 2025, missed forecasts by -100.0%. The prior quarter beat by -157.58%. Over the last six quarters, Apple has recorded several small beats. These include -158.33% in August 14, 2024.

BiomX Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.01. This means the shares are trading above this model’s fair value.

BiomX Inc. (AMEX:PHGE) closed at $2.13 USD, gaining $0.25 (13.30%) from the previous close of $1.88. The stock is currently mid-range between its 52-week high and low $1.50 and $22.06. With a market capitalization of about $3.25 million, BiomX Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.57). Key stats such as the average daily volume over the past year has been around 80.31 thousand shares, in line with its 52-week average. Headquartered in Ness Ziona, None, BiomX Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jonathan Eitan Solomon, the company employs approximately 52 people and listed since March 13, 2019. BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.

BiomX Inc. trades at a P/E ratio of -0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.33 suggesting the stock is closer to book value. The P/FCF stands at -0.11, also above market averages.

BiomX Inc. (AMEX:PHGE) shares are down -84.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BiomX Inc. trading at a premium to the broader market with a P/E of -0.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.00, suggesting 510.33% upside. Our AI forecast model points to short-term weakness (-99.53% over two weeks), a medium-term rise (538.5% over three months), and a longer-term loss (-76.06% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that BiomX Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -99.53%, with price expected at $0.01 by January 02, 2026, within a range of $0.00 to $0.71 3-Month Outlook: Projected rise of 538.5%, reaching $13.60 by March 19, 2026, with a range of $7.87 to $18.51. 1-Year Outlook: Projected loss of -76.06%, with price at $0.51 by December 18, 2026, within a range of $0.00 to $4.92.